

# Cristina Mussini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5561527/publications.pdf>

Version: 2024-02-01

410  
papers

17,187  
citations

20817

60  
h-index

21540

114  
g-index

417  
all docs

417  
docs citations

417  
times ranked

21546  
citing authors

#	ARTICLE	IF	CITATIONS
1	Early awake proning in critical and severe COVID-19 patients undergoing noninvasive respiratory support: A retrospective multicenter cohort study. <i>Pulmonology</i> , 2022, 28, 181-192.	2.1	32
2	What have we learned from the first to the second wave of COVID-19 pandemic? An international survey from the ESCMID Study Group for Infection in the Elderly (ESGIE) group. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 281-288.	2.9	8
3	Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106492.	2.5	6
4	Resilience and Frailty in People Living With HIV During the COVID Era: Two Complementary Constructs Associated With Health-Related Quality of Life. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, S65-S72.	2.1	6
5	Acid base disorders in patients with COVID-19. <i>International Urology and Nephrology</i> , 2022, 54, 405-410.	1.4	26
6	Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac003.	0.9	18
7	First and second waves among hospitalised patients with COVID-19 with severe pneumonia: a comparison of 28-day mortality over the 1-year pandemic in a tertiary university hospital in Italy. <i>BMJ Open</i> , 2022, 12, e054069.	1.9	13
8	Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort. <i>Viruses</i> , 2022, 14, 163.	3.3	5
9	Integrase strand transfer inhibitor use and cancer incidence in a large cohort setting. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac029.	0.9	3
10	Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy—Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac068.	0.9	20
11	Another piece in the COVID-19 treatment puzzle. <i>Lancet, The</i> , 2022, 399, 609-610.	13.7	6
12	Metabolic reprogramming shapes neutrophil functions in severe COVID-19. <i>European Journal of Immunology</i> , 2022, 52, 484-502.	2.9	34
13	Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing <i>Klebsiella pneumoniae</i> : a multicentre study. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, dlac022.	2.1	17
14	Risk Factors for Pulmonary Air Leak and Clinical Prognosis in Patients With COVID-19 Related Acute Respiratory Failure: A Retrospective Matched Control Study. <i>Frontiers in Medicine</i> , 2022, 9, 848639.	2.6	5
15	Association between respiratory distress time and invasive mechanical ventilation in COVID-19 patients: a multicentre regional cohort study. <i>Pulmonology</i> , 2022, , .	2.1	0
16	Plasma Cytokine Atlas Reveals the Importance of TH2 Polarization and Interferons in Predicting COVID-19 Severity and Survival. <i>Frontiers in Immunology</i> , 2022, 13, 842150.	4.8	15
17	Non-B subtypes account for a large proportion of clustered primary HIV-1 infections in Italy. <i>Sexually Transmitted Infections</i> , 2022, , sextrans-2021-055289.	1.9	1
18	Cytomegalovirus blood reactivation in COVID-19 critically ill patients: risk factors and impact on mortality. <i>Intensive Care Medicine</i> , 2022, 48, 706-713.	8.2	39

#	ARTICLE	IF	CITATIONS
19	Long-Term Impact of the COVID-19 Pandemic on In-Hospital Antibiotic Consumption and Antibiotic Resistance: A Time Series Analysis (2015â€“2021). <i>Antibiotics</i> , 2022, 11, 826.	3.7	21
20	Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. <i>Lancet HIV</i> , 2022, 9, e474-e485.	4.7	48
21	Molecular and cellular immune features of aged patients with severe COVID-19 pneumonia. <i>Communications Biology</i> , 2022, 5, .	4.4	27
22	The interplay of post-acute COVID-19 syndrome and aging: a biological, clinical and public health approach. <i>Ageing Research Reviews</i> , 2022, 81, 101686.	10.9	6
23	Two fatal cases of acute liver failure due to HSV-1 infection in COVID-19 patients following immunomodulatory therapies. <i>Clinical Infectious Diseases</i> , 2021, 73, e252-e255.	5.8	39
24	Human Immunodeficiency Virus (HIV) Care Models During the Coronavirus Disease 2019 (COVID-19) Era. <i>Clinical Infectious Diseases</i> , 2021, 73, e1222-e1227.	5.8	30
25	Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. <i>Clinical Infectious Diseases</i> , 2021, 73, 195-202.	5.8	8
26	The Role of the Renin-Angiotensin System in Severe Acute Respiratory Syndrome-CoV-2 Infection. <i>Blood Purification</i> , 2021, 50, 263-267.	1.8	17
27	Never Give Up: Lesson learned from a severe COVID-19 patient. <i>Pulmonology</i> , 2021, 27, 257-260.	2.1	0
28	Efficient T-Cell Compartment in HIV-Positive Patients Receiving Orthotopic Liver Transplant and Immunosuppressive Therapy. <i>Journal of Infectious Diseases</i> , 2021, 223, 482-493.	4.0	0
29	Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant <i>Pseudomonas aeruginosa</i> post-neurosurgical infections: three cases and a review of the literature. <i>Infection</i> , 2021, 49, 549-553.	4.7	17
30	Immunomodulation for the management of severe SARS-CoV2 infections. State of the art and review of the literature. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 151-155.	2.1	2
31	Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1054-1065.	3.4	87
32	Virological response and resistance profile in highly treatmentâ€“experienced HIVâ€“infected patients switching to dolutegravir plus boosted darunavir in clinical practice. <i>HIV Medicine</i> , 2021, 22, 519-525.	2.2	6
33	Adherence to lipid-lowering medication in people living with HIV: An outpatient clinic drug direct distribution experience. <i>Journal of Research in Pharmacy Practice</i> , 2021, 10, 10.	0.7	0
34	Hypokalemia in Patients with COVID-19. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 401-409.	1.6	78
35	Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection. <i>PLoS ONE</i> , 2021, 16, e0247275.	2.5	7
36	Ceftazidime-Avibactam Use for <i>Klebsiella pneumoniae</i> Carbapenemaseâ€“Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 1664-1676.	5.8	130

#	ARTICLE	IF	CITATIONS
37	Patient-reported olfactory recovery after SARS-CoV-2 infection: A 6-month follow-up study. <i>International Forum of Allergy and Rhinology</i> , 2021, 11, 1249-1252.	2.8	24
38	Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen). <i>BMJ Open</i> , 2021, 11, e040210.	1.9	10
39	The Importance of Understanding the Stages of COVID-19 in Treatment and Trials. <i>AIDS Reviews</i> , 2021, 23, 40-47.	1.0	66
40	Prospective Study on Incidence, Risk Factors and Outcome of Recurrent Clostridioides difficile Infections. <i>Journal of Clinical Medicine</i> , 2021, 10, 1127.	2.4	10
41	Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab103.	0.9	8
42	The impact of DAA-mediated HCV eradication on CD4 <sup>+</sup> and CD8 <sup>+</sup> T lymphocyte trajectories in HIV/HCV coinfecting patients: Data from the ICONA Foundation Cohort. <i>Journal of Viral Hepatitis</i> , 2021, 28, 779-786.	2.0	12
43	Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). <i>Clinical Microbiology and Infection</i> , 2021, 27, 389-395.	6.0	37
44	Accuracy of the serological detection of IgG and IgM to SARS-Cov-2: a prospective, cross-sectional study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1891-1898.	2.9	2
45	Risk factors for nosocomial rectal colonization with carbapenem-resistant Acinetobacter baumannii in hospital: a matched case-control study. <i>Antimicrobial Resistance and Infection Control</i> , 2021, 10, 69.	4.1	11
46	NLRP3 and IL-1 $\beta$ Gene Expression Is Elevated in Monocytes From HIV-Treated Patients With Neurocognitive Disorders. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 496-499.	2.1	9
47	Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 283-291.	1.1	4
48	Anti-Tat immunity defines CD4 <sup>+</sup> T-cell dynamics in people living with HIV on long-term cART. <i>EBioMedicine</i> , 2021, 66, 103306.	6.1	11
49	The time to offer treatments for COVID-19. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 505-518.	4.1	20
50	Diagnostic stewardship based on patient profiles: differential approaches in acute versus chronic infectious syndromes. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1373-1383.	4.4	5
51	Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study. <i>Multidisciplinary Respiratory Medicine</i> , 2021, 16, 737.	1.5	3
52	Identification and characterization of a SARS-CoV-2 specific CD8 <sup>+</sup> T cell response with immunodominant features. <i>Nature Communications</i> , 2021, 12, 2593.	12.8	94
53	Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study. <i>Transplant Infectious Disease</i> , 2021, 23, e13608.	1.7	11
54	Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary loss. <i>Scientific Reports</i> , 2021, 11, 9632.	3.3	1

#	ARTICLE	IF	CITATIONS
55	Re: "No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir" by Calza et al. AIDS Research and Human Retroviruses, 2021, 37, 333-334.	1.1	0
56	Twenty-four-hour serum creatinine variation is associated with poor outcome in the novel coronavirus disease 2019 (COVID-19) patients. Kidney Research and Clinical Practice, 2021, 40, 231-240.	2.2	14
57	Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study. Frontiers in Medicine, 2021, 8, 639970.	2.6	20
58	Monocyte Distribution Width (MDW) as novel inflammatory marker with prognostic significance in COVID-19 patients. Scientific Reports, 2021, 11, 12716.	3.3	38
59	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/ $\mu$ L. Journal of the International AIDS Society, 2021, 24, e25726.	3.0	8
60	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. Journal of Healthcare Engineering, 2021, 2021, 1-10.	1.9	2
61	The Impact of COVID-19 on UNAIDS 90-90-90 Targets: Calls for New HIV Care Models. Open Forum Infectious Diseases, 2021, 8, ofab283.	0.9	13
62	Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort. HIV Medicine, 2021, 22, 843-853.	2.2	18
63	Re: "Methodological evaluation of bias in observational COVID-19 studies on drug effectiveness" by Wolkewitz et al.. Clinical Microbiology and Infection, 2021, 27, 1043-1044.	6.0	0
64	Endogenous control of inflammation characterizes pregnant women with asymptomatic or paucisymptomatic SARS-CoV-2 infection. Nature Communications, 2021, 12, 4677.	12.8	29
65	Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008-2018 in Italy. Journal of Clinical Medicine, 2021, 10, 3391.	2.4	3
66	Incidence, risk factors and outcome of acute kidney injury (AKI) in patients with COVID-19. Clinical and Experimental Nephrology, 2021, 25, 1203-1214.	1.6	27
67	The impact of tocilizumab on respiratory support states transition and clinical outcomes in COVID-19 patients. A Markov model multi-state study. PLoS ONE, 2021, 16, e0251378.	2.5	3
68	A five-component infection control bundle to permanently eliminate a carbapenem-resistant <i>Acinetobacter baumannii</i> spreading in an intensive care unit. Antimicrobial Resistance and Infection Control, 2021, 10, 123.	4.1	17
69	Measles-induced immune amnesia likely recorded in the 18th century. Journal of Clinical Virology, 2021, 141, 104899.	3.1	2
70	Better prognosis in females with severe COVID-19 pneumonia: possible role of inflammation as potential mediator. Clinical Microbiology and Infection, 2021, 27, 1137-1144.	6.0	15
71	Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 234-237.	2.1	18
72	Herpes Simplex Virus Re-Activation in Patients with SARS-CoV-2 Pneumonia: A Prospective, Observational Study. Microorganisms, 2021, 9, 1896.	3.6	28

#	ARTICLE	IF	CITATIONS
73	Endobronchial valve positioning for alveolar-pleural fistula following ICU management complicating COVID-19 pneumonia. <i>BMC Pulmonary Medicine</i> , 2021, 21, 307.	2.0	8
74	Inspiratory Effort and Lung Mechanics in Spontaneously Breathing Patients with Acute Respiratory Failure due to COVID-19: A Matched Control Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 725-728.	5.6	41
75	Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3272-3279.	3.0	0
76	Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. <i>Lancet HIV</i> , 2021, 8, e711-e722.	4.7	35
77	Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106406.	2.5	4
78	The role of antimicrobial stewardship in preventing KPC-producing <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, i12-i18.	3.0	5
79	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment—Experienced People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2323-e2333.	5.8	16
80	Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR) <i>Pseudomonas aeruginosa</i> : Resistance Predictors and Impact on Clinical Outcomes Besides Implications for Antimicrobial Stewardship Programs. <i>Antibiotics</i> , 2021, 10, 1224.	3.7	4
81	CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. <i>Clinical Infectious Diseases</i> , 2021, 73, 50-59.	5.8	18
82	Signals were broadly positive for months, but never definitive: the tocilizumab story. <i>Clinical Microbiology and Infection</i> , 2021, , .	6.0	1
83	Acid base disorders in patients with COVID-19. <i>International Urology and Nephrology</i> , 2021, , .	1.4	4
84	Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience. <i>Medicine (United States)</i> , 2021, 100, e27418.	1.0	0
85	Risk factors for functional decline among survivors of Gram-negative bloodstream infection: A prospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0259707.	2.5	1
86	Has COVID-19 changed the approach to HIV diagnosis?. <i>Medicine (United States)</i> , 2021, 100, e27418.	1.0	7
87	Development of post-COVID-19 cardiovascular events: an analysis of clinical features and risk factors from a single hospital retrospective study. <i>Infezioni in Medicina</i> , 2021, 29, 538-549.	1.1	3
88	Reply to De Greef et al. <i>Clinical Infectious Diseases</i> , 2020, 70, 351-353.	5.8	2
89	Cervical cancer risk in women living with HIV across four continents: A multicohort study. <i>International Journal of Cancer</i> , 2020, 146, 601-609.	5.1	37
90	Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Clinical Infectious Diseases</i> , 2020, 71, 1799-1801.	5.8	28

#	ARTICLE	IF	CITATIONS
91	Treating cancer with immunotherapy in HIV-positive patients: A challenging reality. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 145, 102836.	4.4	9
92	COVID-19-associated vasculitis and thrombotic complications: from pathological findings to multidisciplinary discussion. <i>Rheumatology</i> , 2020, 59, e147-e150.	1.9	19
93	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCOVID-19 prospective trial. <i>Journal of Translational Medicine</i> , 2020, 18, 405.	4.4	98
94	Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply. <i>Lancet Rheumatology</i> , The, 2020, 2, e739-e740.	3.9	3
95	A patient-centred approach to deprescribing antiretroviral therapy in people living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3425-3432.	3.0	9
96	Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings. <i>Journal of Clinical Virology</i> , 2020, 130, 104534.	3.1	11
97	Epidemiology and Risk Factors Associated With Mortality in Consecutive Patients With Bacterial Bloodstream Infection: Impact of MDR and XDR Bacteria. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa461.	0.9	41
98	Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1899-1913.	2.6	137
99	Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study). <i>Clinical Microbiology and Infection</i> , 2020, 26, 1545-1553.	6.0	71
100	Epidemiology and clinical outcomes of latent tuberculosis infection in adults affected with acute leukemia or aplastic anemia: a retrospective single-center study. <i>Annals of Hematology</i> , 2020, 99, 2201-2203.	1.8	3
101	Expansion of plasmablasts and loss of memory B cells in peripheral blood from COVID-19 patients with pneumonia. <i>European Journal of Immunology</i> , 2020, 50, 1283-1294.	2.9	95
102	Rituximab in people living with HIV affected by immune-mediated renal diseases: a case-series. <i>International Journal of STD and AIDS</i> , 2020, 31, 1426-1431.	1.1	2
103	TOCOVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol. <i>Contemporary Clinical Trials</i> , 2020, 98, 106165.	1.8	9
104	Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV. <i>Aids</i> , 2020, 34, 1915-1921.	2.2	11
105	Long-term consequences of COVID-19: research needs. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1115-1117.	9.1	241
106	Safety and efficacy of the Russian COVID-19 vaccine: more information needed. <i>Lancet</i> , The, 2020, 396, e53.	13.7	27
107	Tocilizumab for severe COVID-19 pneumonia – Authors' reply. <i>Lancet Rheumatology</i> , The, 2020, 2, e660-e661.	3.9	39
108	Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. <i>European Journal of Internal Medicine</i> , 2020, 82, 38-47.	2.2	88

#	ARTICLE	IF	CITATIONS
109	Epidemiology and Outcomes of Bloodstream Infections in HIV-Patients during a 13-Year Period. <i>Microorganisms</i> , 2020, 8, 1210.	3.6	6
110	Short Communication: Circulating Mitochondrial DNA and Lipopolysaccharide-Binding Protein but Not Bacterial DNA Are Increased in Acute Human Immunodeficiency Virus Infection. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 817-820.	1.1	3
111	A Retrospective Whole-Genome Sequencing Analysis of Carbapenem and Colistin-Resistant <i>Klebsiella pneumoniae</i> Nosocomial Strains Isolated during an MDR Surveillance Program. <i>Antibiotics</i> , 2020, 9, 246.	3.7	12
112	Tocilizumab in patients with severe COVID-19: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e474-e484.	3.9	772
113	Acute Myocarditis as the Main Clinical Manifestation of SARS-CoV 2 Infection. <i>Gastroenterology Insights</i> , 2020, 12, 8609.	1.2	5
114	SARS-CoV-2, the Virus that Causes COVID-19: Cytometry and the New Challenge for Global Health. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2020, 97, 340-343.	1.5	91
115	Considerations for the optimal management of antibiotic therapy in elderly patients. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 22, 325-333.	2.2	27
116	Shall We Dance? Extending TANGO™s Results to Clinical Practice. <i>Clinical Infectious Diseases</i> , 2020, 71, e200-e201.	5.8	6
117	Successful treatment of BK virus associated-nephropathy in a human immunodeficiency virus-positive kidney transplant recipient. <i>International Journal of STD and AIDS</i> , 2020, 31, 387-391.	1.1	2
118	Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. <i>Nature Communications</i> , 2020, 11, 3434.	12.8	636
119	Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV Infection (IN ACTION) cohort. <i>HIV Medicine</i> , 2020, 21, 523-535.	2.2	6
120	Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol. <i>Trials</i> , 2020, 21, 574.	1.6	37
121	Plea for multitargeted interventions for severe COVID-19. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1122-1123.	9.1	18
122	Sex Differences in People Aging With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 284-291.	2.1	22
123	Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 240-250.	2.1	24
124	<sup>18</sup> Fluoride-based molecular imaging of coronary atherosclerosis in HIV infected patients. <i>Atherosclerosis</i> , 2020, 297, 127-135.	0.8	14
125	Acute Myeloid Leukemia in Patients Living with HIV Infection: Several Questions, Fewer Answers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1081.	4.1	10
126	Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales. <i>Antibiotics</i> , 2020, 9, 71.	3.7	68



#	ARTICLE	IF	CITATIONS
127	Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1026-1030.	3.0	20
128	Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepalCONA foundation cohorts. <i>Digestive and Liver Disease</i> , 2020, 52, 447-451.	0.9	1
129	HIV MDR is still a relevant issue despite its dramatic drop over the years. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1301-1310.	3.0	13
130	COVID-19: Importance of the Awareness of the Clinical Syndrome by Urologists. <i>European Urology</i> , 2020, 78, e40-e41.	1.9	24
131	Handling and Processing of Blood Specimens from Patients with COVID-19 for Safe Studies on Cell Phenotype and Cytokine Storm. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2020, 97, 668-673.	1.5	26
132	The Lisbon patient: exceptional longevity with HIV suggests healthy aging as an ultimate goal for HIV care. <i>BMC Infectious Diseases</i> , 2020, 20, 290.	2.9	1
133	Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa139.	0.9	49
134	Comparison of two perioperative antibiotic schedules in patients undergoing surgical reconstruction with dermal matrix after excision of skin cancer. <i>International Wound Journal</i> , 2020, 17, 937-943.	2.9	2
135	Role of Maraviroc in minimizing the risk of graft rejection in HIV-infected kidney transplant recipients. <i>Transplant Infectious Disease</i> , 2020, 22, e13294.	1.7	1
136	RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies. <i>Vascular Pharmacology</i> , 2020, 135, 106805.	2.1	39
137	Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1. <i>HIV Research and Clinical Practice</i> , 2020, 21, 151-167.	1.1	7
138	Changes in central adipose tissue after switching to integrase inhibitors. <i>HIV Research and Clinical Practice</i> , 2020, 21, 168-173.	1.1	10
139	Machine learning in predicting respiratory failure in patients with COVID-19 pneumonia—Challenges, strengths, and opportunities in a global health emergency. <i>PLoS ONE</i> , 2020, 15, e0239172.	2.5	43
140	Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia. <i>EMBO Molecular Medicine</i> , 2020, 12, e13001.	6.9	133
141	Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection—Results of Italian Network of ACuTe HIV InfectiON (INACTiON) Retrospective Study. <i>Pathogens and Immunity</i> , 2020, 5, 8.	3.1	16
142	Prevalence of HIV-associated neurocognitive disorder (HAND) and its subgroups among HIV-positive persons on anti-retroviral therapy in Iran. <i>Psihologija</i> , 2020, 53, 115-127.	0.6	2
143	OUP accepted manuscript. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 265-268.	2.9	16
144	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. <i>PLoS ONE</i> , 2020, 15, e0243625.	2.5	8

#	ARTICLE	IF	CITATIONS
145	Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by <i>Klebsiella pneumoniae</i> Producing Carbapenemase. <i>Clinical Infectious Diseases</i> , 2019, 68, 355-364.	5.8	265
146	Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1443-1446.	6.0	8
147	Antiviral activity of sirolimus in an HIV-positive kidney transplant recipient. <i>International Journal of STD and AIDS</i> , 2019, 30, 919-922.	1.1	7
148	Thymus Imaging Detection and Size Is Inversely Associated With Metabolic Syndrome and Frailty in People With HIV. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz435.	0.9	5
149	Compression of frailty in adults living with HIV. <i>BMC Geriatrics</i> , 2019, 19, 229.	2.7	5
150	Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3295-3304.	3.0	14
151	Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 728-734.	2.5	40
152	A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4 <200 cells/uL (the PRADAR study). <i>PLoS ONE</i> , 2019, 14, e0222650.	2.5	11
153	SAT-159-Genetic determinants in critical domains of NS5A are associated with genotype 1b HCV-induced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, e699-e700.	3.7	0
154	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. <i>Journal of the International AIDS Society</i> , 2019, 22, e25227.	3.0	46
155	Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1363-1367.	3.0	21
156	<i>Rhodococcus equi</i> Pneumonia in Kidney Transplant Recipient Affected by Acute Intermittent Porphyria: A Case Report. <i>Transplantation Proceedings</i> , 2019, 51, 229-234.	0.6	6
157	The Interplay Between Age and Frailty in People Living With HIV: Results From an 11-Year Follow-up Observational Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz199.	0.9	8
158	Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study. <i>HIV Research and Clinical Practice</i> , 2019, 20, 24-33.	1.1	5
159	Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm <sup>3</sup> and HIV-RNA >5 log <sub>10</sub> copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2732-2741.	3.0	11
160	Bloodstream infections caused by carbapenem-resistant <i>Acinetobacter baumannii</i> : Clinical features, therapy and outcome from a multicenter study. <i>Journal of Infection</i> , 2019, 79, 130-138.	3.3	67
161	<i>Granulicatella adiacens</i> and <i>Abiotrophia defectiva</i> Native Vertebral Osteomyelitis: Three Cases and Literature Review of Clinical Characteristics and Treatment Approach. <i>Case Reports in Infectious Diseases</i> , 2019, 2019, 1-8.	0.5	7
162	Impact of genotypic susceptibility score on cART outcomes during primary HIV infection. <i>Journal of Medical Virology</i> , 2019, 91, 1891-1895.	5.0	0

#	ARTICLE	IF	CITATIONS
163	Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy. <i>Sexually Transmitted Infections</i> , 2019, 95, 619-625.	1.9	18
164	Local Epidemics Gone Viral: Evolution and Diffusion of the Italian HIV-1 Recombinant Form CRF60_BC. <i>Frontiers in Microbiology</i> , 2019, 10, 769.	3.5	6
165	Very High Pre-Therapy Viral Load is a Predictor of Virological Rebound in HIV-1-Infected Patients Starting a Modern First-Line Regimen. <i>Antiviral Therapy</i> , 2019, 24, 321-331.	1.0	4
166	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. <i>Lancet, The</i> , 2019, 393, 2428-2438.	13.7	627
167	AGE OF HIV ACQUISITION AFFECTS THE RISK OF MULTI-MORBIDITY AFTER 25 YEARS OF INFECTION EXPOSURE. <i>Journal of Frailty &amp; Aging,the</i> , 2019, 8, 1-5.	1.3	7
168	Molecular Imaging of Vascular Calcification with 18F-Sodium-Fluoride in Patients Infected with Human Immunodeficiency Virus. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1183.	4.1	4
169	Pneumocystosis as a Complication of H1N1 Influenza A Infection in an HIV-Positive Patient on Effective cART. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz105.	0.9	6
170	Reply to MacFadden and Hanage and to Pallett et al. <i>Clinical Infectious Diseases</i> , 2019, 69, 1263-1264.	5.8	0
171	Establishing a hepatitis C continuum of care among <scp>HIV</scp>/hepatitis C virusâ€œcoinfected individuals in Euro<scp>SIDA</scp>. <i>HIV Medicine</i> , 2019, 20, 264-273.	2.2	9
172	The dynamic association between Frailty, CD4 and CD4/CD8 ratio in people aging with HIV. <i>PLoS ONE</i> , 2019, 14, e0212283.	2.5	24
173	Cohort profile: The Observational cohort for the study of Dolutegravir in Antiretroviral Combination REgimens (ODOACRE). <i>BMJ Open</i> , 2019, 9, e029960.	1.9	12
174	Breast tuberculosis: A case report of primary type mammary tuberculosis. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2346-2348.	0.5	1
175	Long-term virological suppression on first-line efavirenzâ€Š+â€Štenofovirâ€Š+â€Šemtricitabine/lamivudine for HIV-1. <i>Aids</i> , 2019, 33, 745-751.	2.2	3
176	Aging with HIV. <i>Current HIV/AIDS Reports</i> , 2019, 16, 475-481.	3.1	63
177	Altered Expression of PYCARD, Interleukin 1 $\beta$ , Interleukin 18, and NAIP in Successfully Treated HIV-Positive Patients With a Low Ratio of CD4+ to CD8+ T Cells. <i>Journal of Infectious Diseases</i> , 2019, 219, 1743-1748.	4.0	8
178	Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2019, 69, 1091-1098.	5.8	256
179	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet, The</i> , 2019, 393, 143-155.	13.7	265
180	Ceftolozane/tazobactam for the treatment of serious <i>Pseudomonas aeruginosa</i> infections: a multicentre nationwide clinical experience. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 408-415.	2.5	120

#	ARTICLE	IF	CITATIONS
181	Migration and health: A retrospective study about the prevalence of HBV, HIV, HCV, tuberculosis and syphilis infections amongst newly arrived migrants screened at the Infectious Diseases Unit of Modena, Italy. <i>Journal of Infection and Public Health</i> , 2019, 12, 200-204.	4.1	19
182	Optimization strategies for HIV, hepatitis and syphilis testing in Infectious Disease Clinic and Dermatology Unit of Modena: 7-year results of collaboration experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 959-965.	2.4	4
183	Mortality in Patients With Septic Shock by Multidrug Resistant Bacteria. <i>Journal of Intensive Care Medicine</i> , 2019, 34, 48-54.	2.8	34
184	Title is missing!. , 2019, 14, e0222650.		0
185	Title is missing!. , 2019, 14, e0222650.		0
186	Title is missing!. , 2019, 14, e0222650.		0
187	Title is missing!. , 2019, 14, e0222650.		0
188	Viro-Immunological Response of Drug-Naive HIV-1-Infected Patients Starting a First-Line Regimen with Viraemia >500,000 Copies/ml in Clinical Practice. <i>Antiviral Therapy</i> , 2018, 23, 249-257.	1.0	10
189	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. <i>Clinical Infectious Diseases</i> , 2018, 66, 893-903.	5.8	105
190	Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. <i>HIV Clinical Trials</i> , 2018, 19, 52-60.	2.0	6
191	Highlights of the 2017 European <sc>AIDS</sc> Clinical Society (EACS) Guidelines for the treatment of adult <sc>HIV</sc>-positive persons version 9.0. <i>HIV Medicine</i> , 2018, 19, 309-315.	2.2	77
192	Indications for starting ART. <i>Lancet HIV</i> , 2018, 5, e157-e158.	4.7	2
193	Re: Lebentrau S, Gilfrich C, Vetterlein MW, Schumacher H, Spachmann PJ, Brookman-May SD, Fritsche HM, Schostak M, Wagenlehner F, Burger M, May M, MR2 study group (2017) Impact of the medical specialty on knowledge regarding multidrug-resistant organisms and strategies toward antimicrobial stewardship. <i>Int Urol Nephrol</i> 49:1311-1318. <i>International Urology and Nephrology</i> . 2018. 50. 873-874.	1.4	0
194	Gastric Mucormycosis in a Liver and Kidney Transplant Recipient: Case Report and Concise Review of Literature. <i>Transplantation Proceedings</i> , 2018, 50, 905-909.	0.6	11
195	The extent of B-cell activation and dysfunction preceding lymphoma development in <sc>HIV</sc>-positive people. <i>HIV Medicine</i> , 2018, 19, 90-101.	2.2	14
196	Bacterial pneumonia in patients with liver cirrhosis, with or without HIV co-infection: a possible definition of antibiotic prophylaxis associated pneumonia (APAP). <i>Infectious Diseases</i> , 2018, 50, 125-132.	2.8	4
197	Non-Hodgkin lymphoma risk in adults living with HIV across five continents. <i>Aids</i> , 2018, 32, 2777-2786.	2.2	10
198	Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalence. <i>Scientific Reports</i> , 2018, 8, 15739.	3.3	2

#	ARTICLE	IF	CITATIONS
199	Managing antiretroviral therapy in the elderly HIV patient. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 1171-1181.	3.1	9
200	Incidence of HCV infection amongst HIV positive men who had sex with men and prevalence data from patients followed at the Infectious Diseases Clinic of Modena, Italy. <i>Digestive and Liver Disease</i> , 2018, 50, 1334-1338.	0.9	3
201	Construct validation of a Frailty Index, an HIV Index and a Protective Index from a clinical HIV database. <i>PLoS ONE</i> , 2018, 13, e0201394.	2.5	10
202	The degree of HIV-1 amino acid variability is strictly related to different disease progression rates. <i>Virus Genes</i> , 2018, 54, 493-501.	1.6	4
203	Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. <i>BMC Medicine</i> , 2018, 16, 79.	5.5	24
204	Immunophenotypic profile and clinical outcome of monoclonal Bâ€cell lymphocytosis in kidney transplantation. <i>Clinical Transplantation</i> , 2018, 32, e13338.	1.6	5
205	Evolution of HIV-1 transmitted drug resistance in Italy in the 2007â€2014 period: A weighted analysis. <i>Journal of Clinical Virology</i> , 2018, 106, 49-52.	3.1	8
206	Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. <i>BMC Public Health</i> , 2018, 18, 870.	2.9	19
207	Clinical outcome of kidney transplantation in HIV-infected recipients: a retrospective study. <i>International Journal of STD and AIDS</i> , 2018, 29, 1305-1315.	1.1	16
208	Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. <i>Journal of Clinical Virology</i> , 2018, 104, 61-64.	3.1	19
209	Treatment rate for HCV in the direct-acting antivirals era in HIV co-infected patients: data from an Italian cohort. <i>Minerva Medica</i> , 2018, 109, 203-210.	0.9	4
210	Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy113.	0.9	56
211	Exploring viral reservoir: The combining approach of cell sorting and droplet digital PCR. <i>Methods</i> , 2018, 134-135, 98-105.	3.8	18
212	Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015. <i>Eurosurveillance</i> , 2018, 23, .	7.0	12
213	European Society of Cardiology-Proposed Diagnostic Echocardiographic Algorithm in Elective Patients with Clinical Suspicion of Infective Endocarditis: Diagnostic Yield and Prognostic Implications in Clinical Practice. <i>Journal of Cardiovascular Echography</i> , 2018, 28, 26.	0.4	4
214	Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment. <i>New Microbiologica</i> , 2018, 41, 112-117.	0.1	3
215	Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. <i>New Microbiologica</i> , 2018, 41, 247-255.	0.1	11
216	Cardiovascular disease in women with HIV-1 infection. <i>International Journal of Cardiology</i> , 2017, 241, 50-56.	1.7	14

#	ARTICLE	IF	CITATIONS
217	Acute human herpes virus 7 (HHV-7) encephalitis in an immunocompetent adult patient: a case report and review of literature. <i>Infection</i> , 2017, 45, 385-388.	4.7	14
218	HIV-DNA content in different CD4 + T-cell subsets correlates with CD4 + cell. <i>Aids</i> , 2017, 31, 1387-1392.	2.2	15
219	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 1316-1326.	5.8	44
220	Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. <i>BMC Infectious Diseases</i> , 2017, 17, 215.	2.9	76
221	Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000â€“14. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2837-2845.	3.0	15
222	Clinical Utility of Epstein-Barr Virus Viral Load Monitoring and Risk Factors for Posttransplant Lymphoproliferative Disorders After Kidney Transplantation: A Single-Center, 10-Year Observational Cohort Study. <i>Transplantation Direct</i> , 2017, 3, e182.	1.6	10
223	Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains. <i>Journal of Clinical Microbiology</i> , 2017, 55, 2827-2837.	3.9	18
224	Correlates of frailty phenotype and frailty index and their associations with clinical outcomes. <i>HIV Medicine</i> , 2017, 18, 764-771.	2.2	44
225	Brief Report: Drop in CD4+ Counts Below 200 Cells/µL After Reaching (or Starting From) Values Higher than 350 Cells/µL in HIV-Infected Patients With Virological Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 417-422.	2.1	2
226	Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe. <i>Aids</i> , 2017, 31, 835-846.	2.2	14
227	Late presentation increases risk and costs of non-infectious comorbidities in people with HIV: an Italian cost impact study. <i>AIDS Research and Therapy</i> , 2017, 14, 8.	1.7	31
228	Higher rates of tripleâ€“class virological failure in perinatally <sc>HIV</sc>-infected teenagers compared with heterosexually infected young adults in Europe. <i>HIV Medicine</i> , 2017, 18, 171-180.	2.2	45
229	Lower Frailty Is Associated with Successful Cognitive Aging Among Older Adults with HIV. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 157-163.	1.1	35
230	Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients. <i>Annals of Internal Medicine</i> , 2017, 166, 9.	3.9	41
231	Impact of polypharmacy on antiretroviral prescription in people living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 511-514.	3.0	21
232	Virological response and resistance profile in HIVâ€“1â€“infected patients starting darunavirâ€“containing regimens. <i>HIV Medicine</i> , 2017, 18, 21-32.	2.2	9
233	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2869-2878.	3.0	17
234	Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icoha cohort. <i>PLoS ONE</i> , 2017, 12, e0177402.	2.5	15

#	ARTICLE	IF	CITATIONS
235	A frailty index predicts post-liver transplant morbidity and mortality in HIV-positive patients. <i>AIDS Research and Therapy</i> , 2017, 14, 37.	1.7	19
236	Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians. <i>BMC Infectious Diseases</i> , 2017, 17, 734.	2.9	4
237	Impact of Pre-Analytical Time on the Recovery of Pathogens from Blood Cultures: Results from a Large Retrospective Survey. <i>PLoS ONE</i> , 2017, 12, e0169466.	2.5	29
238	Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. <i>PLoS ONE</i> , 2017, 12, e0171611.	2.5	10
239	Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. <i>PLoS ONE</i> , 2017, 12, e0173893.	2.5	30
240	Predictors of transitions in frailty severity and mortality among people aging with HIV. <i>PLoS ONE</i> , 2017, 12, e0185352.	2.5	33
241	State of the Art of Dual Therapy in 2015. <i>AIDS Reviews</i> , 2017, 17, .	1.0	4
242	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016. <i>New Microbiologica</i> , 2017, 40, 86-98.	0.1	19
243	Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study. <i>Drug Design, Development and Therapy</i> , 2016, 10, 1589.	4.3	6
244	Benefits and medium-term outcome of the Sorin Pericarbon Freedom stentless aortic prosthesis in cases of acute bacterial endocarditis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2016, 23, 593-598.	1.1	3
245	Discontinuation of Initial Antiretroviral Therapy in Clinical Practice. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 263-271.	2.1	39
246	European <sc>AIDS</sc> Clinical Society Standard of Care meeting on <sc>HIV</sc> and related coinfections: The Rome Statements. <i>HIV Medicine</i> , 2016, 17, 445-452.	2.2	8
247	Th1 and Th17 proinflammatory profile characterizes invariant natural killer T cells in virologically suppressed HIV+ patients with low CD4+/CD8+ ratio. <i>Aids</i> , 2016, 30, 2599-2610.	2.2	30
248	Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1-18.	3.3	49
249	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 58-64.	2.1	128
250	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw519.	5.8	20
251	Prediction of hard cardiovascular events in HIV patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3515-3518.	3.0	20
252	Antimicrobial stewardship in a Gastroenterology Department: Impact on antimicrobial consumption, antimicrobial resistance and clinical outcome. <i>Digestive and Liver Disease</i> , 2016, 48, 1142-1147.	0.9	22

#	ARTICLE	IF	CITATIONS
253	Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA. <i>Journal of Clinical Virology</i> , 2016, 82, 94-100.	3.1	35
254	Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies. <i>Clinical Infectious Diseases</i> , 2016, 63, 1373-1379.	5.8	25
255	The cardiovascular risk management for people living with HIV in Europe. <i>Aids</i> , 2016, 30, 2505-2518.	2.2	27
256	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 565-575.	9.1	217
257	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1352-1360.	3.0	4
258	Evaluation of serum (1 $\rightarrow$ 3)- $\beta$ -D-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors. <i>Infection</i> , 2016, 44, 223-233.	4.7	27
259	Ageing and inflammation in patients with HIV infection. <i>Clinical and Experimental Immunology</i> , 2016, 187, 44-52.	2.6	214
260	Mucorales-Specific T Cells in Patients with Hematologic Malignancies. <i>PLoS ONE</i> , 2016, 11, e0149108.	2.5	40
261	In Virologically Suppressed HIV+ Patients, High CD4/CD8 Ratio and Length of Treatment Independently Correlate to the Intracellular Content of Proviral HIV-DNA in Different Types of CD4+ T Cells. <i>Blood</i> , 2016, 128, 3704-3704.	1.4	0
262	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015. <i>New Microbiologica</i> , 2016, 39, 93-109.	0.1	13
263	Decrease of renal function in HCV and HIV/HCV-infected patients with telaprevir-based therapy. <i>Aids</i> , 2015, 29, 2061-2062.	2.2	2
264	Analysis of inflammasomes and antiviral sensing components reveals decreased expression of NLRX1 in HIV-positive patients assuming efficient antiretroviral therapy. <i>Aids</i> , 2015, 29, 1937-1941.	2.2	18
265	A frailty index predicts survival and incident multimorbidity independent of markers of HIV disease severity. <i>Aids</i> , 2015, 29, 1633-1641.	2.2	136
266	Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord. <i>BMC Infectious Diseases</i> , 2015, 15, 498.	2.9	3
267	HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. <i>Retrovirology</i> , 2015, 12, 33.	2.0	55
268	Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. <i>PLoS ONE</i> , 2015, 10, e0140877.	2.5	7
269	Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?. <i>Aids</i> , 2015, 29, 2323-2333.	2.2	21
270	Mortality in migrants living with HIV in western Europe (1997-2013): a collaborative cohort study. <i>Lancet HIV</i> , 2015, 2, e540-e549.	4.7	19



#	ARTICLE	IF	CITATIONS
271	CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. <i>Lancet HIV</i> , 2015, 2, e98-e106.	4.7	249
272	Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2935-2941.	3.9	6
273	Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naïve adults. <i>Aids</i> , 2015, 29, 193-200.	2.2	13
274	Epidemiology and clinical outcome of lower respiratory tract infections by respiratory syncytial virus or parainfluenza virus type 3 in adults receiving treatment for either acute leukemia or severe aplastic anemia: a retrospective single center study. <i>Annals of Hematology</i> , 2015, 94, 1931-1934.	1.8	5
275	Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non-AIDS-Defining Events in a Large Cohort of HIV-Infected Patients. <i>Journal of Infectious Diseases</i> , 2015, 211, 178-186.	4.0	146
276	Reliable and Accurate CD4+ T Cell Count and Percent by the Portable Flow Cytometer CyFlow MiniPOC and "CD4 Easy Count Kit-Dry", as Revealed by the Comparison with the Gold Standard Dual Platform Technology. <i>PLoS ONE</i> , 2015, 10, e0116848.	2.5	10
277	Aging with HIV vs. HIV Seroconversion at Older Age: A Diverse Population with Distinct Comorbidity Profiles. <i>PLoS ONE</i> , 2015, 10, e0118531.	2.5	81
278	Timing of Antiretroviral Therapy Initiation after a First AIDS-Defining Event: Temporal Changes in Clinical Attitudes in the ICONA Cohort. <i>PLoS ONE</i> , 2014, 9, e89861.	2.5	3
279	Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort. <i>Journal of the International AIDS Society</i> , 2014, 17, 19825.	3.0	5
280	CD4/CD8 ratio is not predictive of multi-morbidity prevalence in HIV-infected patients but identify patients with higher CVD risk. <i>Journal of the International AIDS Society</i> , 2014, 17, 19709.	3.0	16
281	An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy. <i>Journal of the International AIDS Society</i> , 2014, 17, 19771.	3.0	2
282	Burden of subclinical heart and lung disease detected on thoracic CT scans of HIV patients on HAART. <i>Journal of the International AIDS Society</i> , 2014, 17, 19716.	3.0	3
283	Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. <i>Journal of the International AIDS Society</i> , 2014, 17, 19769.	3.0	4
284	Predictors of emphysema progression in HIV-positive patients. <i>Journal of the International AIDS Society</i> , 2014, 17, 19660.	3.0	1
285	Successful Treatment of HIV-1 Infection Increases the Expression of a Novel, Short Transcript for IL-18 Receptor Î± Chain. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 254-257.	2.1	9
286	The Problem of Renal Function Monitoring in Patients Treated With the Novel Antiretroviral Drugs. <i>HIV Clinical Trials</i> , 2014, 15, 87-91.	2.0	12
287	The natural history of HIV-associated lipodystrophy in the changing scenario of HIV infection. <i>HIV Medicine</i> , 2014, 15, 587-594.	2.2	26
288	Persistent inflammation in HIV infection: Established concepts, new perspectives. <i>Immunology Letters</i> , 2014, 161, 184-188.	2.5	61

#	ARTICLE	IF	CITATIONS
289	Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. <i>Infection</i> , 2014, 42, 61-71.	4.7	7
290	Intact parathyroid hormone levels are associated with increased carotid intima media thickness in HIV infected patients. <i>Atherosclerosis</i> , 2014, 237, 618-622.	0.8	6
291	Liver Enzyme Elevation During Darunavir-Based Antiretroviral Treatment in HIV-1 Infected Patients With or Without Hepatitis C Coinfection: Data from the ICONA Foundation Cohort. <i>HIV Clinical Trials</i> , 2014, 15, 151-160.	2.0	10
292	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. <i>Clinical Infectious Diseases</i> , 2014, 58, 1312-1321.	5.8	140
293	The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. <i>Retrovirology</i> , 2014, 11, 49.	2.0	48
294	Aging with HIV infection: A journey to the center of inflammAIDS, immunosenescence and neuroHIV. <i>Immunology Letters</i> , 2014, 162, 329-333.	2.5	59
295	Combination therapy for carbapenem-resistant Gram-negative bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2305-2309.	3.0	179
296	Effectiveness and durability of darunavir/ritonavir (DRV/r) in DRV/r-experienced HIV-1-infected patients in routine clinical practice. <i>Journal of the International AIDS Society</i> , 2014, 17, 19786.	3.0	1
297	Monitoring renal function during combination therapy with telaprevir in HIV/HCV co-infected patients with advanced/fibrosis cirrhosis. <i>Journal of the International AIDS Society</i> , 2014, 17, 19627.	3.0	2
298	Life Expectancy in the Immune Recovery Era. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 175-181.	2.1	23
299	Novel antiretroviral drugs and renal function monitoring of HIV patients. <i>AIDS Reviews</i> , 2014, 16, 144-51.	1.0	31
300	Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir. <i>Infection</i> , 2013, 41, 425-429.	4.7	4
301	Cytometry, immunology, and HIV infection: Three decades of strong interactions. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2013, 83A, 680-691.	1.5	11
302	Drug-resistance development differs between HIV-1 infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. <i>HIV Medicine</i> , 2013, 14, 571-577.	2.2	7
303	Characteristics and outcome predictors of patients involved in an outbreak of <i>Burkholderia cepacia</i> complex. <i>Journal of Hospital Infection</i> , 2013, 85, 73-75.	2.9	5
304	Novel genetic association of TNF- $\pm$ 238 and PDCD1-7209 polymorphisms with long-term non-progressive HIV-1 infection. <i>International Journal of Infectious Diseases</i> , 2013, 17, e845-e850.	3.3	14
305	Inverse Correlation Between Vascular Calcification and Bone Mineral Density in Human Immunodeficiency Virus-Infected Patients. <i>Calcified Tissue International</i> , 2013, 93, 413-418.	3.1	8
306	Predictors of CD4+ T-Cell Counts of HIV Type 1 Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. <i>Journal of Infectious Diseases</i> , 2013, 207, 759-767.	4.0	7

#	ARTICLE	IF	CITATIONS
307	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count $\geq 200$ Cells/ $\mu$ L in the Post-Combination Antiretroviral Therapy Era. <i>Clinical Infectious Diseases</i> , 2013, 57, 1038-1047.	5.8	92
308	Who is more likely to respond to dual treatment with pegylated interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. <i>Journal of Viral Hepatitis</i> , 2013, 20, 790-800.	2.0	11
309	Impact of Pre-Therapy Viral Load on Virological Response to Modern First-Line Haart. <i>Antiviral Therapy</i> , 2013, 18, 867-876.	1.0	34
310	Incidence, Timing, and Determinants of Bacterial Pneumonia Among HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 339-345.	2.1	14
311	CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE. <i>PLoS Medicine</i> , 2012, 9, e1001194.	8.4	145
312	All-cause mortality in treated HIV-infected adults with CD4 $\geq 500$ /mm <sup>3</sup> compared with the general population: evidence from a large European observational cohort collaboration. <i>International Journal of Epidemiology</i> , 2012, 41, 433-445.	1.9	217
313	Mitochondrial DNA: a proinflammatory "enemy from within" during HIV infection?. <i>Cell Death and Disease</i> , 2012, 3, e307-e307.	6.3	18
314	The protease inhibitor atazanavir triggers autophagy and mitophagy in human preadipocytes. <i>Aids</i> , 2012, 26, 2017-2026.	2.2	46
315	Mitochondrial DNA Haplogroups and Incidence of Lipodystrophy in HIV-Infected Patients on Long-Term Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 113-120.	2.1	29
316	Aseptic Osteonecrosis. <i>Transplantation</i> , 2012, 94, e20-e21.	1.0	0
317	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 119-127.	9.1	41
318	Stable changes in CD4+ T lymphocyte miRNA expression after exposure to HIV-1. <i>Blood</i> , 2012, 119, 6259-6267.	1.4	83
319	T Cell Activation but Not Polyfunctionality after Primary HIV Infection Predicts Control of Viral Load and Length of the Time without Therapy. <i>PLoS ONE</i> , 2012, 7, e50728.	2.5	19
320	Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, , 1.	2.1	3
321	Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 294-299.	2.1	13
322	Renal complications in HIV disease: between present and future. <i>AIDS Reviews</i> , 2012, 14, 37-53.	1.0	29
323	Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. <i>New Microbiologica</i> , 2012, 35, 17-25.	0.1	19
324	HIV-1 Infection and the Aging of the Immune System: Facts, Similarities and Perspectives. <i>Journal of Experimental and Clinical Medicine</i> , 2011, 3, 143-150.	0.2	15

#	ARTICLE	IF	CITATIONS
325	Increased plasma levels of extracellular mitochondrial DNA during HIV infection: A new role for mitochondrial damage-associated molecular patterns during inflammation. <i>Mitochondrion</i> , 2011, 11, 750-755.	3.4	84
326	Survival Outcomes and Effect of Early vs. Deferred cART Among HIV-Infected Patients Diagnosed at the Time of an AIDS-Defining Event: A Cohort Analysis. <i>PLoS ONE</i> , 2011, 6, e26009.	2.5	16
327	Decline of CD4+ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals. <i>Aids</i> , 2011, 25, 1041-1049.	2.2	14
328	CD4+ T-cell differentiation, regulatory T cells and gag-specific T lymphocytes are unaffected by CD4-guided treatment interruption and therapy resumption. <i>Aids</i> , 2011, 25, 1443-1453.	2.2	16
329	Decreased mitochondrial DNA content in subcutaneous fat from HIV-infected women taking antiretroviral therapy as measured at delivery. <i>Antiviral Therapy</i> , 2011, 16, 365-72.	1.0	12
330	Late Presenters in New HIV Diagnoses from An Italian Cohort of HIV-Infected Patients: Prevalence and Clinical Outcome. <i>Antiviral Therapy</i> , 2011, 16, 1103-1112.	1.0	45
331	Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. <i>BMC Infectious Diseases</i> , 2011, 11, 23.	2.9	5
332	NK-cell phenotype at interruption underlies widely divergent duration of CD4+-guided antiretroviral treatment interruption. <i>International Immunology</i> , 2011, 23, 109-118.	4.0	14
333	T Cell Homeostasis in Centenarians: From the Thymus to the Periphery. <i>Current Pharmaceutical Design</i> , 2010, 16, 597-603.	1.9	23
334	Upregulation of nuclear-encoded mitochondrial LON protease in HAART-treated HIV-positive patients with lipodystrophy: implications for the pathogenesis of the disease. <i>Aids</i> , 2010, 24, 841-850.	2.2	35
335	Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. <i>Archives of Internal Medicine</i> , 2010, 170, 410-419.	3.8	42
336	Is There Any Potential for First-Line Etravirine Use? Analysis From a Large Data Set of Antiretroviral Therapy-Naive HIV-Infected Patients Undergoing Resistance Test. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 150-151.	2.1	0
337	Patients presenting with AIDS: still a clinical challenge. <i>Future Virology</i> , 2010, 5, 17-19.	1.8	0
338	Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients. <i>Antiviral Therapy</i> , 2010, 15, 51-59.	1.0	21
339	Predicting the magnitude of short-term CD4 <sup>+</sup> T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 165-175.	1.0	16
340	Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART. <i>PLoS ONE</i> , 2010, 5, e13540.	2.5	94
341	One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. <i>Patient Preference and Adherence</i> , 2010, 4, 115.	1.8	130
342	Is It Safe to Discontinue Primary <i>Pneumocystis jirovecii</i> Pneumonia Prophylaxis in Patients with Virologically Suppressed HIV Infection and a CD4 Cell Count $\geq 200$ Cells/ $\mu$ L?. <i>Clinical Infectious Diseases</i> , 2010, 51, 611-619.	5.8	96

#	ARTICLE	IF	CITATIONS
343	Incidence of Malignancies in HIV-Infected Patients and Prognostic Role of Current CD4 Cell Count: Evidence from a Large Italian Cohort Study. <i>Clinical Infectious Diseases</i> , 2010, 50, 1316-1321.	5.8	56
344	Transmitted HIV Type 1 Drug Resistance and Non-B Subtypes Prevalence among Seroconverters and Newly Diagnosed Patients from 1992 to 2005 in Italy. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 41-49.	1.1	15
345	Pretreatment CD4 Cell Slope and Progression to AIDS or Death in HIV-Infected Patients Initiating Antiretroviral Therapy—The CASCADE Collaboration: A Collaboration of 23 Cohort Studies. <i>PLoS Medicine</i> , 2010, 7, e1000239.	8.4	54
346	Cytotoxic granule release dominates gag-specific CD4+ T-cell response in different phases of HIV infection. <i>Aids</i> , 2010, 24, 947-957.	2.2	45
347	Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per $\mu$ L in Europe and North America: a pooled cohort observational study. <i>Lancet, The</i> , 2010, 376, 340-345.	13.7	82
348	Predictive Value of Intracellular HIV-1 DNA Levels During CD4-Guided Treatment Interruption in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 553-558.	1.1	10
349	Incidence, Temporal Trends, and Predictors of Thrombocytopenia Among HIV-Infected Persons Treated with Combined Antiretroviral Therapy (cART). <i>Blood</i> , 2010, 116, 69-69.	1.4	0
350	Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. <i>New Microbiologica</i> , 2010, 33, 195-206.	0.1	35
351	Performance of Tests for Latent Tuberculosis in Different Groups of Immunocompromised Patients. <i>Chest</i> , 2009, 136, 198-204.	0.8	137
352	Common Genetic Variation and the Control of HIV-1 in Humans. <i>PLoS Genetics</i> , 2009, 5, e1000791.	3.5	377
353	Risk of Developing Specific AIDS-Defining Illnesses in Patients Coinfected with HIV and Hepatitis C Virus With or Without Liver Cirrhosis. <i>Clinical Infectious Diseases</i> , 2009, 49, 612-622.	5.8	53
354	Two Different Patterns of Mutations are Involved in the Genotypic Resistance Score for Atazanavir Boosted Versus Unboosted by Ritonavir in Multiple Failing Patients. <i>Infection</i> , 2009, 37, 233-243.	4.7	9
355	Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Naïve to Antiretroviral Therapy. <i>Infection</i> , 2009, 37, 270-82.	4.7	7
356	HIV-Infected long-term nonprogressors display a unique correlative pattern between the interleukin-7/interleukin-7 receptor circuit and T-cell homeostasis. <i>HIV Medicine</i> , 2009, 10, 422-431.	2.2	11
357	Magnitude and Determinants of CD4 Recovery After HAART Resumption After 1 Cycle of Treatment Interruption. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 588-594.	2.1	9
358	Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. <i>Annals of Neurology</i> , 2008, 63, 213-221.	5.3	167
359	Mitochondrial DNA Haplogroups and Highly Active Antiretroviral Therapy-Related Lipodystrophy. <i>Clinical Infectious Diseases</i> , 2008, 47, 962-968.	5.8	26
360	Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. <i>Aids</i> , 2008, 22, 1769-1778.	2.2	48

#	ARTICLE	IF	CITATIONS
361	Late Presenters in an HIV Surveillance System in Italy During the Period 1992-2006. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 49, 282-286.	2.1	74
362	Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. <i>Aids</i> , 2008, 22, 2461-2469.	2.2	51
363	Effects of the Change From Stavudine to Tenofovir in Human Immunodeficiency Virus-Infected Children Treated With Highly Active Antiretroviral Therapy. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, 17-21.	2.0	21
364	Gram-Positive Bloodstream Infections in Liver Transplant Recipients: Incidence, Risk Factors, and Impact on Survival. <i>Transplantation Proceedings</i> , 2007, 39, 1947-1949.	0.6	27
365	Identification and characterization of an aspartyl protease from <i>Cryptococcus neoformans</i> . <i>FEBS Letters</i> , 2007, 581, 3882-3886.	2.8	18
366	Differential course of HIV-1 infection and apolipoprotein E polymorphism. <i>Open Medicine (Poland)</i> , 2007, 2, 404-416.	1.3	1
367	Congenital Pyelectasis in Children Born from Mothers on Tenofovir Containing Therapy During Pregnancy: Report of Two Cases. <i>Infection</i> , 2007, 35, 474-476.	4.7	10
368	Observational Study on HIV-Infected Subjects Failing HAART Receiving Tenofovir Plus Didanosine as NRTI Backbone. <i>Infection</i> , 2007, 35, 451-456.	4.7	3
369	Use in routine clinical practice of two commercial blood tests for diagnosis of infection with <i>Mycobacterium tuberculosis</i> : a prospective study. <i>Lancet, The</i> , 2006, 367, 1328-1334.	13.7	468
370	Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system. <i>Aids</i> , 2006, 20, 2021-2032.	2.2	20
371	Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. <i>Clinical Microbiology and Infection</i> , 2006, 12, 75-80.	6.0	81
372	Baseline HIV RNA and the when to start question: time to stop asking this question?. <i>Aids</i> , 2006, 20, 1197-1198.	2.2	0
373	Access to gynecological services and Papanicolau tests in HIV-infected Italian women: A questionnaire survey. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2006, 18, 376-378.	1.2	5
374	Interruption of Highly Active Antiretroviral Therapy in HIV Clinical Practice. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 38, 407-416.	2.1	46
375	Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study. <i>Aids</i> , 2005, 19, 1627-1633.	2.2	56
376	Genetic polymorphisms of Fas (CD95) and Fas ligand (CD178) influence the rise in CD4+ T cell count after antiretroviral therapy in drug-naïve HIV-positive patients. <i>Immunogenetics</i> , 2005, 57, 628-635.	2.4	44
377	Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America. <i>Clinical Infectious Diseases</i> , 2005, 41, 1772-1782.	5.8	197
378	Increased urinary coproporphyrin excretion observed in patients with differently staged Hodgkin's disease treated with chemotherapy. <i>Pharmacological Research</i> , 2005, 51, 283-288.	7.1	4

#	ARTICLE	IF	CITATIONS
379	CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 10 <sup>6</sup> cells/l. <i>Aids</i> , 2005, 19, 287-94.	2.2	24
380	Altered Mitochondrial Rna Production in Adipocytes from HIV-Infected Individuals with Lipodystrophy. <i>Antiviral Therapy</i> , 2005, 10, 91-99.	1.0	24
381	Changes in Mitochondrial Rna Production in Cells Treated with Nucleoside Analogues. <i>Antiviral Therapy</i> , 2005, 10, 191-195.	1.0	37
382	Discontinuation of Maintenance Therapy for Cryptococcal Meningitis in Patients with AIDS Treated with Highly Active Antiretroviral Therapy: An International Observational Study. <i>Clinical Infectious Diseases</i> , 2004, 38, 565-571.	5.8	118
383	The human immunodeficiency virus (HIV) protease inhibitor indinavir directly affects the opportunistic fungal pathogen <i>Cryptococcus neoformans</i> . <i>FEMS Immunology and Medical Microbiology</i> , 2004, 42, 187-195.	2.7	23
384	Prevalence, Associated Factors, and Prognostic Determinants of AIDS-Related Toxoplasmic Encephalitis in the Era of Advanced Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2004, 39, 1681-1691.	5.8	131
385	Mitochondrial membrane potential and nucleosidic inhibitors of HIV reverse transcriptase: a cytometric approach. <i>Mitochondrion</i> , 2004, 4, 271-278.	3.4	10
386	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet, The</i> , 2004, 364, 51-62.	13.7	303
387	Highly Active Antiretroviral Therapy Restores CD4+ V?? T-Cell Repertoire in Patients With Primary Acute HIV Infection But Not in Treatment-Naive HIV+ Patients With Severe Chronic Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 35, 213-222.	2.1	25
388	Increased excretion of urine coproporphyrins during daunorubicin administration in patients affected by acute myelogenous leukemia. <i>Pharmacological Research</i> , 2003, 48, 515-518.	7.1	0
389	Discontinuation of Secondary Prophylaxis for <i>Pneumocystis carinii</i> Pneumonia in Human Immunodeficiency Virus-Infected Patients: A Randomized Trial by the CIOP Study Group. <i>Clinical Infectious Diseases</i> , 2003, 36, 645-651.	5.8	39
390	Access to Antiretroviral Treatment, Incidence of Sustained Therapy Interruptions, and Risk of Clinical Events According to Sex. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, 184-190.	2.1	64
391	Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. <i>New England Journal of Medicine</i> , 2003, 349, 1993-2003.	27.0	1,560
392	MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. <i>Aids</i> , 2003, 17, 1696-1698.	2.2	77
393	Different Sensitivity to Apoptosis in Cells of Monocytic or Lymphocytic Origin Chronically Infected with Human Immunodeficiency Virus Type-1. <i>Experimental Biology and Medicine</i> , 2003, 228, 1346-1354.	2.4	15
394	Increased Mitochondrial Dna Content in Peripheral Blood Lymphocytes from HIV-Infected Patients with Lipodystrophy. <i>Antiviral Therapy</i> , 2003, 8, 315-321.	1.0	64
395	Mitochondrial Functionality and Mitochondrial DNA Content in Lymphocytes of Vertically Infected Human Immunodeficiency Virus-Positive Children with Highly Active Antiretroviral Therapy-Related Lipodystrophy. <i>Journal of Infectious Diseases</i> , 2002, 185, 299-305.	4.0	90
396	Physician Estimates of Adherence and the Patient-Physician Relationship as a Setting to Improve Adherence to Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 31, S158-S162.	2.1	55

#	ARTICLE	IF	CITATIONS
397	Features of 'CD4-exploders', HIV-positive patients with an optimal immune reconstitution after potent antiretroviral therapy. <i>Aids</i> , 2002, 16, 1609-1616.	2.2	48
398	Kinetics of CD4 cells after discontinuation of antiretroviral therapy in patients with virological failure and a CD4 cell count greater than 500 cells/ $\mu$ l. <i>Aids</i> , 2002, 16, 1551-1554.	2.2	17
399	Markers of cell death-activation in lymphocytes of vertically HIV-infected children naive to highly active antiretroviral therapy: The role of age. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 108, 439-445.	2.9	14
400	Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders?. <i>BioEssays</i> , 2001, 23, 1070-1080.	2.5	42
401	Low Frequency of Severe Hepatotoxicity and Association With HCV Coinfection in HIV-Positive Patients Treated With HAART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 28, 114-123.	2.1	79
402	Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infection. <i>Aids</i> , 2000, 14, 345-355.	2.2	30
403	Discontinuation of Primary Prophylaxis for <i>Pneumocystis carinii</i> Pneumonia and Toxoplasmic Encephalitis in Human Immunodeficiency Virus Type 1-Infected Patients: The Changes in Opportunistic Prophylaxis Study. <i>Journal of Infectious Diseases</i> , 2000, 181, 1635-1642.	4.0	103
404	Quantitation of CD95 and CD95L mRNA Expression in Chronic and Acute HIV-1 Infection by Competitive RT-PCR. <i>Annals of the New York Academy of Sciences</i> , 2000, 926, 46-51.	3.8	6
405	Differential down-regulation of CD95 or CD95L in chronically HIV-infected cells of monocytic or lymphocytic origin: cellular studies and molecular analysis by quantitative competitive RT-PCR. <i>FEBS Letters</i> , 1999, 458, 209-214.	2.8	14
406	Apoptotic Features of Peripheral Blood Granulocytes and Monocytes during Primary, Acute HIV Infection. <i>Experimental Cell Research</i> , 1999, 247, 304-311.	2.6	17
407	Mitochondria alterations and dramatic tendency to undergo apoptosis in peripheral blood lymphocytes during acute HIV syndrome. <i>Aids</i> , 1997, 11, 19-26.	2.2	118
408	Massive Activation of Immune Cells with an Intact T Cell Repertoire in Acute Human Immunodeficiency Virus Syndrome. <i>Journal of Infectious Diseases</i> , 1995, 172, 105-112.	4.0	72
409	Effect of amrinone on myocardial mitochondria function. <i>FEBS Letters</i> , 1988, 233, 400-402.	2.8	2
410	Mixed connective tissue disease (Sharp syndrome): Description of two cases. <i>Italian Journal of Neurological Sciences</i> , 1983, 4, 203-205.	0.1	2